WXXWY WUXI BIOLGCS ADR
- 3.680
- +0.140+3.95%
WUXI BIOLGCS ADR News
Hong Kong Stock Afternoon Review | The three major indices rose sharply, domestic housing stocks and biotech stocks strengthened, Shimao Group rose more than 42%, and Ziding Pharmaceutical rose nearly 17%
Science and network stocks generally rose; Meituan rose more than 4%, and Bilibili rose nearly 3%; shipping stocks generally rose, with COSCO Maritime Control rising by more than 6%, and Orient Overseas International rising more than 5%.
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Glonghui, May 9 | Jefferies released a report saying that from the perspective of market accounts, Yao Ming Biotech is currently at an inflection point, and it is believed that its risk and reward curves tend to rise more than decline. The bank gave it a “buy” rating, with a target price of HK$53. Jefferies pointed out that investors are reaching consensus on the geopolitical issues faced by Pharmacovigilance. As the US Biological Act progresses, in particular, how to handle existing contracts will become more clear. Jeffrey explained that investors currently assume that the bill will be passed in some form; the bill should not be as severe as it seems, and they estimate that new projects from Yao Ming Biotech and even its Chinese counterpart will be in the next 3 to
The Hong Kong stock CXO concept fluctuated and strengthened, and Pharmaceutical Biotech rose more than 5%
The CXO concept of Hong Kong stocks fluctuated and strengthened. Yao Ming Biotech rose more than 5%, Kanglong Chemical and Pharmaceutical Kangde rose more than 4%, and Kingsley Biotech and Zhaoyan Pharmaceutical followed suit.
The biomedical sector of Hong Kong stocks strengthened, and BaiGene rose more than 5%
Glonghui, May 9 | BeiGene's increase extended to more than 5%, Pharmaceutical Biotech and Rongchang Biotech rose nearly 3%, and Cansino Biotech rose more than 1%.
Research and Development | China Merchants Securities: Drastic reduction in the target price of Pharmaceutical Biotech to HK$13, downgrading the rating to “neutral”
Glonghui, May 8 | China Merchants Securities issued a report, arguing that the hawkish monetary policy of the Federal Reserve will slow down the recovery of drug development and manufacturing (CDMO) performance in the current fiscal year. It is expected that the possibility that Yao Ming Biotech's revenue will increase by medium to high units in this fiscal year will decrease, so its target price was drastically lowered from HK$45 to HK$13, and the rating was downgraded from “increase in holdings” to “neutral”. The bank lowered Yao Ming Biotech's revenue and adjusted net profit forecasts for the current fiscal year by 12% and 17%, respectively, to reflect a further slowdown in the company's overall revenue growth. According to China Merchants Securities, downgrading Yao Ming Biotech this time is counterproductive
May 7 Repurchase Collection | Kuaishou-W, Hang Seng Bank and others bought back one after another, of which Kuaishou-W cost HK$49.499 million
According to documents disclosed by the Hong Kong Stock Exchange on May 8, $Kuaishou-W (01024.HK) $, $Hang Seng Bank (00011.HK) $, etc. repurchased shares. ① $Kuaishou-W (01024.HK) $ repurchased 844,000 shares of the same share with different rights on May 7, involving an amount of HK$49.499 million. The repurchase price for each share ranged from HK$59.95 to HK$58.5. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 58.722,300 shares, accounting for 1.355% of the number of shares issued when the ordinary resolution was passed. ②
Pharmaceutical Biotech (02269) spent HK$198292 million to buy back 1.37 million shares on May 7
Pharmaceutical Biotech (02269) announced that on May 7, 2024, the company spent HK$198292 million...
A quick look at the Hong Kong market | The three major indices have collectively pulled back, and the science index fell more than 2% to 4,000 points; domestic housing stocks rose against the market, and Xincheng Development rose nearly 6%
Technology Network stocks generally fell; Bilibili fell more than 6%, Kuaishou fell nearly 5%, and Meituan fell nearly 4%; copper concept stocks strengthened, Wanguo International Mining rose nearly 10%, and China's nonferrous mining industry rose more than 4%.
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Hong Kong Stock Afternoon Review | The three major indices fluctuated slightly, pharmaceutical stocks strengthened against the market, and Pharmaceutical Biotech rose more than 5%
Most Technet stocks weakened, with Kuaishou falling nearly 2%, Meituan, Xiaomi, and Bilibili falling more than 1%; travel and tourism stocks generally rising, with Ctrip Group rising nearly 3%, Hong Kong China Travel up more than 2%, and Tongcheng Travel up more than 1%.
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
Changes in Hong Kong stocks | Yao Ming Biotech rose more than 7% to lead CRO concept stocks. The Federal Reserve may still cut interest rates during the year, and overseas demand is expected to resume
On May 6, CRO concept stocks had the highest gains in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 6.82% to HK$36.8; Pharmaceutical Biotech (02269) rose 5.87% to HK$36.45; Kanglong Chemical (03759) rose 4.92% to HK$10.44; and Pharmaceuticals Kangde (02359) rose 3.14% to HK$37.75.
Express News | Most Hong Kong pharmaceutical outsourcing concept stocks strengthened, and Pharmaceutical Biotech rose more than 6%
Hong Kong CXO concept stocks fluctuated higher, and Pharmaceutical Biotech rose more than 8%
Hong Kong stock CXO concept stocks fluctuated higher. Pharmaceutical Biotech rose more than 8%, Tiger Pharmaceuticals and Kanglong Chemical rose more than 5%, and Pharmaceutical Kangde and Kingsley Biotech had the highest gains.
Hong Kong stocks started “booming” in May! The Hang Seng Index reclaimed the 18,000 mark, and in April, Demon Stock added another 30% assist
On May 2, Hong Kong stocks ushered in the first trading day of May, and the three major stock indexes continued their major counterattack!
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Pharmaceutical Biotech Releases 2023 ESG Report Highlights Strong Commitment to Sustainable Development
The company keeps its promises, takes social responsibility, and works with customers around the world to create long-term value for all stakeholders. The company has made significant progress on climate change, reducing the intensity of Scope 1 and Scope 2 greenhouse gas emissions by 29% compared to the 2020 base year. The company achieved the water saving target of reducing water density by 18% by 2025 ahead of schedule, and further upgraded the target to 30%. The company has more than 12,000 employees from 56 countries around the world, with women accounting for 53% of employees in science, technology, engineering and mathematics (STEM) positions. The company gained mainstream
Express News | Fidelity's emerging market fund of over $20 billion increased its holdings in TSMC, reduced Ali's holdings, and opened a position with Pharmaceutical Biotech
Analysis
Price Target
No Data
